Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
22 Results for "
mouse pancreatic islets
" in MedChemExpress (MCE) Product Catalog:
Products (22)
22 Results for "mouse pancreatic islets" in MCE Product Catalog:
7
7 Publications Verification
Cat. No.: HY-16307
CAS No.: 261365-11-1
Target:
Research Areas:
MB05032 is a fructose-1,6-bisphosphatase (FBP1/FBPase) inhibitor with an IC50 value of 16 nM. MB05032 blocks FBP1-mediated glycolysis inhibition in NK cells, restores NK cell glucose uptake, lactate production, degranulation, perforin production, and cytotoxicity against gastric cancer cells. MB05032 elevates ATP/ADP ratios, increases glucose utilization, and enhances insulin secretion in pancreatic β-cells. MB05032 increases neutrophil adhesion, phagocytosis, and mRNA abundance of HKII, ITGA9, CD36 in subclinically hypocalcemic dairy cows. MB05032 inhibits gluconeogenesis in hepatocytes, acts as the active metabolite of prodrug Managlinat dialanetil (MB06322) (HY-14955). MB05032 can be used for the research of gastric cancer, type 2 diabetes, subclinical hypocalcemia, and insulin resistance .
1
1 Cited Publications
Cat. No.: HY-W017387
CAS No.: 4502-00-5
Synonyms: Sodium 4-methyl-2-oxopentanoate; 2-Ketoisocaproic acid sodium salt
Research Areas:
Sodium α-ketoisocaproate (Sodium 4-methyl-2-oxopentanoate) is an insulin secretagogue. Sodium α-ketoisocaproate undergoes transamination catalyzed by BCAT and BCATm to produce α-ketoglutarate and leucine; it also binds to the SUR1 site to inhibit KATP channel activity, but does not directly affect the Kir6.2 subunit. Sodium α-ketoisocaproate regulates Ca 2+ influx. Sodium α-ketoisocaproate exerts insulinotropic activity in pancreatic islets and intact mouse pancreata with sufficient BCATm expression. Sodium α-ketoisocaproate can be used in research related to type 2 diabetes .
1
1 Cited Publications
Cat. No.: HY-P75178
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: GAD2; Glutamate Decarboxylase 65 KDa Isoform; Glutamate Decarboxylase 2; GAD-65; GAD65; Glutamate Decarboxylase 2 (pancreatic islets And Brain, 65kD); 65 KDa Glutamic Acid Decarboxylase; Glutamate Decarboxylase-2 (Pancreas); Glutamate Decarboxylase 2 (Pan
Species:
Mouse
Source:
Sf9 insect cells
Cat. No.: HY-P10735
CAS No.: 181591-59-3
Synonyms: Gastric inhibitory polypeptide(mouse); GIP(1-42) (mouse)
Research Areas:
Cat. No.: HY-P1745
CAS No.: 163364-16-7
Synonyms: Insulin B chain (9-23)
Target:
Research Areas:
Cat. No.: HY-P990254
Target:
Research Areas:
Synonyms: 5,6-EET; (±)5,6-EpETrE
Target:
Research Areas:
5,6-Epoxyeicosatrienoic acid (5,6-EET; (±)5,6-EpETrE) is a fully racemic version of the enantiomeric forms biosynthesized from arachidonic acid by cytochrome P450 enzymes. In solution, 5,6-Epoxyeicosatrienoic acid degrades into 5,6-DiHET and 5,6-δ-lactone, which can be converted to 5,6-DiHET and quantified by GC-MS. In neuroendocrine cells, such as the anterior pituitary and pancreatic islets, 5,6-Epoxyeicosatrienoic acid has been implicated in the mobilization of calcium and hormone secretion. 5,6-Epoxyeicosatrienoic acid is an inhibitor of T-type voltage-gated calcium channels (Cav3) that inhibits isoforms Cav3.1, Cav3.2 (IC50=0.54 μM), and Cav3. and decreases nifedipine-resistant phenylephrine-induced vasoconstriction in isolated mouse mesenteric arteries via Cav3.2 blockade when used at a concentration of 3 μM. In addition, it is a substrate of COX-1 and COX-2.
Cat. No.: HY-P2612
CAS No.: 199999-60-5
Target:
Research Areas:
Research Areas:
KU14R, an imidazole analog of efaroxan, is a putative imidazoline I3 receptor antagonist and reversible KATP channel inhibitor. KU14R inhibits KATP channel activity in mouse pancreatic β cells with an IC50 of 31.9 μmol/L, and also suppresses Kir6.2 ΔC26 channel activity. KU14R exerts model-dependent antagonistic effects on imidazoline-sensitive insulin secretion. KU14R can be used in the research of diabetes-related diseases .
Cat. No.: HY-W017387S
CAS No.: 93523-67-2
Synonyms: Sodium 4-methyl-2-oxopentanoate-d3; 2-Ketoisocaproic acid-d3 sodium salt
Cat. No.: HY-P1532
CAS No.: 90419-12-8
Synonyms: Rat pancreatic polypeptide
Pancreatic Polypeptide, rat (Rat pancreatic polypeptide) is a rat-derived Pancreatic Polypeptide. Pancreatic Polypeptide is a preferential agonist of NPYR4. Pancreatic Polypeptide, rat protects cells against Streptozotocin (HY-13753)-induced DNA damage. Pancreatic Polypeptide, rat inhibits glucose-stimulated insulin secretion. Pancreatic Polypeptide, rat (TFA) can be used in diabetes-related research .
Cat. No.: HY-120287
CAS No.: 214348-67-1
Target:
Research Areas:
L-054522 is an agonist for somatostatin receptor subtype 2 with Kd of 0.01 nM. L-054522 inhibits growth hormone release from rat primary pituitary cell (IC50=0.05 nM) and glucagon and insulin release from isolated mouse pancreatic islet cell (IC50=0.05 nM and 12 nM) .
Cat. No.: HY-P0262
CAS No.: 138579-66-5
Target:
Research Areas:
Neurological Disease Metabolic Disease Inflammation/Immunology Endocrinology
Cat. No.: HY-174559
Target:
Research Areas:
Human PAX4 mRNA encodes the human paired box 4 (PAX4) protein, a member of the paired box (PAX) family. PAX4 is involved in pancreatic islet development and mouse studies have demonstrated a role for this gene in differentiation of insulin-producing beta cells.
Cat. No.: HY-D3174
CAS No.: 2688758-23-6
Cat. No.: HY-188129
CAS No.: 2889348-10-9
Target:
Research Areas:
GLP-1R modulator-2 is a GLP-1R positive allosteric modulator with an EC50 of 106 nM. GLP-1R modulator-2 simultaneously binds to the extracellular pocket of GLP-1R and the peptide ligand GLP-1 (9-36) through a molecular glue-like allosteric effect, and selectively enhances GLP-1 (9-36)-induced G protein-dependent cAMP signaling. When used in combination with GLP-1 (9-36) under high-glucose conditions, GLP-1R modulator-2 enhances glucose-dependent insulin secretion in wild-type rat pancreatic islets. GLP-1R modulator-2 exhibits strong probe dependence and significantly potentiates the activity of GLP-1 (9-36). GLP-1R modulator-2 can be used for research on type 2 diabetes and obesity .
Cat. No.: HY-139792
CAS No.: 1177460-72-8
Synonyms: SHR117887
Target:
Research Areas:
Besigliptin tosylate (SHR117887) is a DPP-4 inhibitor with activity to improve metabolic control and β-cell function. Besigliptin tosylate can effectively reduce serum DPP-4 activity and improve oral glucose tolerance. Besigliptin tosylate significantly reduces fasting blood glucose levels and improves lipid profiles in a diabetic mouse model. The effect of besigliptin tosylate is comparable to that of the known compound vildagliptin (HY-14291) at the same concentration. Besigliptin tosylate increases insulin staining of pancreatic islet cells in chronic administration, indicating improved β-cell function .
Cat. No.: HY-P75177
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: GAD2; Glutamate Decarboxylase 65 KDa Isoform; Glutamate Decarboxylase 2; GAD-65; GAD65; Glutamate Decarboxylase 2 (pancreatic islets And Brain, 65kD); 65 KDa Glutamic Acid Decarboxylase; Glutamate Decarboxylase-2 (Pancreas); Glutamate Decarboxylase 2 (Pan
Species:
Mouse
Source:
Sf9 insect cells
Cat. No.: HY-184326
CAS No.: 3080324-43-9
Research Areas:
DRAK2-IN-2 is a selective DRAK2 inhibitor with an IC50 value of 198.5 nM. DRAK2-IN-2 inhibits DRAK2-mediated phosphorylation of ULK1 at the Ser56 site. DRAK2-IN-2 enhances insulin secretion, increases mitochondrial membrane potential, alleviates Palmitic acid (HY-N0830)-induced mitochondrial membrane potential damage and Apoptosis, and improves glucose tolerance in vivo. DRAK2-IN-2 can be used for the research of type 2 diabetes .
Cat. No.: HY-183871
CAS No.: 1253197-38-4
Target:
Research Areas:
WMS-1410 is a selective GluN2B-containing NMDA receptor inhibitor with an IC50 of 18.4 nM. WMS-1410 regulates intracellular calcium levels and protects cells from Apoptosis. WMS-1410 inhibits glutamate-induced excitotoxicity. WMS-1410 reverses NMDA/glycine-induced reduction in glucose-stimulated insulin secretion without altering physiological insulin secretion or baseline redox status, but fails to counteract insulin content loss induced by glucolipotoxicity. WMS-1410 exhibits analgesic activity against advanced neuropathic pain. WMS-1410 can be used in studies related to stroke, brain injury, Alzheimer's disease, Parkinson's disease, type 2 diabetes, and neuropathic pain .
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
